Search Results - "Bewshea, C."

Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study by Walker, G. J., Moore, L., Heerasing, N., Hendy, P., Perry, M. H., McDonald, T. J., Debenham, T., Bethune, R., Bewshea, C., Hyde, C., Heap, G. A., Singh, A., Calvert, C., Kennedy, N. A., Goodhand, J. R., Ahmad, T.

“…Summary Background Primary care faecal calprotectin testing distinguishes inflammatory bowel disease (IBD) from functional gut disorder in young patients…”
Get full text

Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report by Carrieri, D, Bewshea, C, Walker, G, Ahmad, T, Bowen, W, Hall, A, Kelly, S

“…Current guidelines on consenting individuals to participate in genomic research are diverse. This creates problems for participants and also for researchers,…”
Get full text

P580 Iron deficiency anaemia and quality of life in Inflammatory Bowel Disease: Prospective cohort study of ferric derisomaltose on quality of life and work productivity in patients with IBD by Goodhand, J R, Parkinson, M, Bewshea, C, Ahmad, T, Kennedy, N A

Get full text

OP11 Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD Bioresource by Roberts, C, Sazonovs, A, Smith, R, Bishara, M, Lin, S, Neil, C, Bewshea, C, Warden, S, Pele, L, Cocking, L, Goodhand, J, Kennedy, N, Parkes, M, Ahmad, T

Get full text

P798 Understanding anti-TNF treatment failure: mechanisms and management of loss of response to anti-TNF therapy, three-year data from the PANTS study by Chanchlani, N, Lin, S, Hamilton, B, Bewshea, C, Thomas, A, Smith, R, Roberts, C, Nice, R, McDonald, T J, Goodhand, J R, Ahmad, T, Kennedy, N A

Get full text

P662 Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease by Lin, S, Chanchlani, N, Smith, R, Roberts, C, Nice, R, McDonald, T J, Hamilton, B, Bewshea, C, Kennedy, N A, Goodhand, J R, Ahmad, T

Get full text

P649 Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease? by Carbery, I, Lin, S, Chanchlani, N, Janjua, M, Nice, R, McDonald, T J, Bewshea, C, Kennedy, N A, Ahmad, T, Goodhand, J R, Selinger, C P

Get full text

P852 Metataxonomic and metabolomic profiling to predict response to anti-TNF therapy in Crohn’s Disease by Foyzul, J, Alexander, J L, Chappell, K E, Ibraheim, H A, Saifuddin, A, Kennedy, N A, Bewshea, C, Lin, S, Hart, A L, Goodhand, J R, Ahmad, T, Powell, N

Get full text

P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic by Lin, S, Bewshea, C, Chanchlani, N, Chee, D, Pollok, R C, Kennedy, N A, Ahmad, T, Goodhand, J R

Get full text

DOP88 Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s disease by Lin, S, Hannon, E, Waring, J F, Reppell, M, Smaoui, N, Pivorunas, V L, Guay, H, Chanchlani, N, Bewshea, C, Bai, B Y H, Kennedy, N A, Goodhand, J R, Mill, J, Ahmad, T

Get full text

OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service by Nice, R, Chanchlani, N, Green, H, Bewshea, C, Kennedy, N, Ahmad, T, Goodhand, J, McDonald, T, Perry, M

“…Abstract Background Anti-drug antibodies can affect biopharmaceutical pharmacokinetics by increasing or decreasing drug clearance. Drug-tolerant (total),…”
Get full text

OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study by Liu, Z, Le, K, Zhou, X, Alexander, J, Lin, S, Bewshea, C, Chanchlani, N, Nice, R, McDonald, T, Lamb, C, Sebastian, S, Kok, K, Lees, C, Hart, A, Pollok, R, Boyton, R, Altmann, D, Pollock, K, Goodhand, J, Kennedy, N, Ahmad, T, Powell, N

Get full text

P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy by Liu, Z, Alexander, J, Le, K, Zhou, X, Ibraheim, H, Anandabaskaran, S, Saifuddin, A, Lin, K, Mcfarlane, L, Anand, N, Constable, L, Castro-Seoane, R, Nice, R, Bewshea, C, D'Mello, A, Jones, G R, Balarajah, S, Fiorentino, F, Sebastian, S, Irving, P, Hicks, L, Williams, H, Kent, A, Linger, R, Parkes, M, Kok, K, Patel, K V, Teare, J, Altmann, D, Hart, A, Lees, C, Boyton, R, Goodhand, J, Kennedy, N, Pollock, K, Ahmad, T, Powell, N

Get full text

OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab by Alexander, J, Kennedy, N, Ibraheim, H, Anandabaskaran, S, Saifuddin, A, Castro Seoane, R, Liu, Z, Nice, R, Bewshea, C, D’Mello, A, Constable, L, Jones, G R, Balarajah, S, Fiorentino, F, Sebastian, S, Irving, P M, Hicks, L, Williams, H, Kent, A, Linger, R, King, R, Parkes, M, Kok, K, Patel, K, Altmann, D, Boyton, R, Goodhand, J, Hart, A, Lees, C, Ahmad, T, Powell, N

Get full text

OP031 Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study by Kennedy, N A, Heap, G, Hamilton, B, Walker, G J, Bewshea, C, Bouri, S, Goodhand, J, Ahmad, T

“…Abstract Background PANTS (Personalised Anti-TNF Therapy in Crohn’s disease [CD]) is a 3-year prospective observational UK-wide study investigating primary…”
Get full text

P793 Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance by Heerasing, N, Hendy, P J, Moore, L, Walker, G J, Bewshea, C, Ahmad, T, Goodhand, J, Kennedy, N A

“…Abstract Background Patients diagnosed with inflammatory bowel disease (IBD) with colonic involvement have increased risk of colorectal cancer (CRC)…”
Get full text

OP03 Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab by Kennedy, N A, Goodhand, J, Bewshea, C, Nice, R, Chee, D, Lin, S, Chanchlani, N, Butterworth, J, Cooney, R, Croft, N, Hart, A, Irving, P, Kok, K, Lamb, C, Limdi, J, MacDonald, J, McGovern, D, Mehta, S, Murray, C, Patel, K, Pollok, R, Raine, T, Russell, R, Selinger, C, Smith, P, Bowden, J, McDonald, T, Lees, C, Sebastian, S, Powell, N, Ahmad, T

Get full text

P182 Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease by Walker, G, Lin, S, Chanchlani, N, Thomas, A, Moore, L, Hendy, P, Heerasing, N, Green, H, Bewshea, C, Goodhand, J, Kennedy, N, Ahmad, T

“…Abstract Background International cohort studies have previously identified Crohn’s disease (CD), ileal disease, smoking, and age (<40 years old) as factors…”
Get full text

OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients by Lin, S, Kennedy, N A, Saifuddin, A, Muñoz Sandoval, D, Reynolds, C J, Seoane, R C, Kottoor, S H, Pieper, F P, Lin, K M, Butler, D K, Chanchlani, N, Nice, R, Chee, D, Bewshea, C, Janjua, M, McDonald, T J, Sebastian, S, Alexander, J L, Constable, L, Lee, J C, Murray, C D, Hart, A L, Irving, P M, Jones, G R, Kok, K B, Lamb, C A, Lees, C W, Altmann, D M, Boyton, R J, Goodhand, J R, Powell, N, Ahmad, T

Get full text

OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease by Sazonovs, A, Kennedy, N A, Bewshea, C, Moutsianas, L, Walker, G J, De Lange, K, Goodhand, J, Anderson, C, Barrett, J, Ahmad, T

“…Abstract Background Immunogenicity to anti-TNF therapy is a major cause of loss of response, treatment discontinuation and hypersensitivity reactions and…”
Get full text